Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06769620 · ClinicalTrials.gov registry record · Phase 1
A First in Human Study of ORT247 in Healthy Volunteers
A Phase 1 study of Amyotrophic Lateral Sclerosis (ALS), sponsored by Orthogonal Neuroscience.
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
- 1
- Study location
NCT06769620 is a Phase 1 study of Amyotrophic Lateral Sclerosis (ALS) that has completed, run by Orthogonal Neuroscience. The registered enrollment target is 44 participants, below the 259-participant average among 17 other Amyotrophic Lateral Sclerosis (ALS) trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06769620, a Phase 1 study of Amyotrophic Lateral Sclerosis (ALS), has completed, sponsored by Orthogonal Neuroscience.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single center, double-blinded, randomized, placebo controlled single ascending dose clinical study, with the primary purpose of evaluating the safety, tolerability, pharmacokinetics (PK), and immunohistochemistry of escalating intravenous doses of ORT247 in healthy volunteers.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ORT247
Study Locations (1)
Texas
- Worldwide Clinical Trials - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2022-06-06 |
| Est. Completion | 2023-10-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06769620
The ClinicalTrials.gov registry entry for NCT06769620 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 259-participant average among 17 other Amyotrophic Lateral Sclerosis (ALS) trials with a reported enrollment target (83% lower). The listed sponsor is Orthogonal Neuroscience, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Amyotrophic Lateral Sclerosis (ALS) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06769620 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06769620 about?
NCT06769620 is a clinical study titled "A First in Human Study of ORT247 in Healthy Volunteers". This is a single center, double-blinded, randomized, placebo controlled single ascending dose clinical study, with the primary purpose of evaluating the safety, tolerability, pharmacokinetics (PK), and immunohistochemistry of escalating intravenous doses of ORT247 in healthy volunteers.
What is the current status of trial NCT06769620?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2022-06-06. Estimated completion is 2023-10-24.
What conditions does trial NCT06769620 study?
This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis (ALS).
What interventions are being tested in trial NCT06769620?
The interventions under investigation include: Placebo (DRUG), ORT247 (DRUG).
Who is sponsoring clinical trial NCT06769620?
This trial is sponsored by Orthogonal Neuroscience, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06769620 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyotrophic Lateral Sclerosis (ALS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
RECRUITING · Phase 1
-
Intestinal Microbiome Transplant in ALS
RECRUITING · Phase 1
-
Investigating the Impact of Electrical Stimulation on Facial Pain, Jaw Movement and Oral Health in People With Motor Neuron Disease.
RECRUITING · NA
-
Healing ALS Registry Observational Study (HAROS)
RECRUITING
-
Mitochondrial Capacity Boost in ALS (MICABO-ALS) Trial
RECRUITING · Phase 2
-
Study of COYA 302 for the Treatment of ALS
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.